Pre-made Ipilimumab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ipilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
| Products Name (INN Index) | Pre-Made Ipilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody |
|---|---|
| INN Name | Ipilimumab |
| Target | CTLA4 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | 5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2005 |
| Year Recommended | 2006 |
| Companies | Aduro BioTech,AIO Studien gGmbH,Australian and New Zealand Urogenital and Prostate Cancer Group,Bavarian Nordic,Big Ten Cancer Research Consortium,BioGene Pharmaceutical,Bristol-Myers Squibb,Canadian |
| Conditions Approved | Malignant melanoma,Renal cell carcinoma |
| Conditions Active | Colorectal cancer,Non-small cell lung cancer,Gastric cancer,Glioblastoma,Head and neck cancer,Mesothelioma,Oesophageal cancer,Prostate cancer,Small cell lung cancer,Urogenital cancer,Adrenocortical c |
| Conditions Discontinued | HIV infections,Lymphoma |
| Development Tech | Medarex UltiMAb Mouse |
| Previous Name | NA |
| Gm Offical Target Name | CTLA4 |
| Package |
